ImmuneAGE Bio

Executive Summary

ImmuneAGE Bio is a Swiss biotechnology company founded in 2022 and headquartered in Basel, dedicated to pioneering therapies that target immune aging. The company leverages small molecules and cell & gene therapy modalities to address the underlying mechanisms of immunosenescence, aiming to treat a spectrum of age-related diseases such as chronic inflammation, autoimmunity, and diminished vaccine response. By focusing on rejuvenating the aging immune system, ImmuneAGE Bio seeks to shift the paradigm from treating individual age-related conditions to modifying the core aging process itself. Their platform integrates insights from immunology and geroscience to discover and develop first-in-class therapeutics with the potential to improve healthspan across multiple indications. Despite being at an early stage, ImmuneAGE Bio has positioned itself at the intersection of two rapidly advancing fields—aging research and immunotherapy. The company’s strategy involves advancing a dual pipeline of small molecule immunomodulators and engineered cell therapies, which could offer both near-term and long-term clinical opportunities. However, as a pre-clinical entity with no disclosed funding rounds or partnerships, the company faces significant challenges in validation and capital raising. Success will depend on generating robust preclinical proof-of-concept data, securing strategic investment, and establishing collaborations with academic or industry leaders. ImmuneAGE Bio’s unique focus on immune aging differentiates it in a competitive landscape, and its progress in the coming quarters will be critical to its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing70% success
• Q4 2026Lead Program IND-Enabling Studies Initiation50% success
• Q2 2027First Preclinical Proof-of-Concept Data Release60% success